Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04652700
Status:
COMPLETED
Last Update Posted:
2023-08-21
First Post:
2020-12-02
Brief Title:
Oral Islatravir MK-8591 Once-Monthly as Preexposure Prophylaxis PrEP in Men and Transgender Women Who Are at High Risk for HIV-1 Infection MK-8591-024
Sponsor:
Organization:
Merck Sharp Dohme LLC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
494
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: